Importantly, individuals who exceeded the amyloid PET–inferred tauopathy cut‐offs showed faster subsequent cognitive decline, consistent with tau pathology being the key driver of cognitive decline in AD.21, 22, 71. This evidence concerns the gene MAPT and Alzheimer disease.